Clinerion, ACRES Partner on Patient Recruitment and Risk-Based Quality Management
eClinical technology services provider Clinerion and the Alliance for Clinical Research Excellence and Safety (ACRES) announced their partnership for accelerating patient recruitment and promoting risk-based quality management.
eClinical technology services provider Clinerion and the Alliance for Clinical Research Excellence and Safety (ACRES) announced their partnership for accelerating patient recruitment and promoting risk-based quality management. The partnership joins ACRES study and site information with Clinerion's Quality Risk Radar solution to significantly extend support of risk-informed decision making during the clinical planning and execution process. Clinerion also will provide ACRES with real-time access to millions of electronic health records (EHRs) coupled with the use of its Patient Recruitment System to find on average 30 times more trial candidates than conventional screening. Read the full release here.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
